Wednesday, 18 November 2026 SEC EDGAR filings, as they land
ALFA USA News Straight from the SEC filing
SEC Filings
Clinical Trial Data

NeOnc Technologies Reports 12.5% Response Rate in NEO100 Brain Cancer Clinical Trial

NeOnc Technologies has announced updated Phase 2a clinical results for its lead candidate NEO100, showing an improved objective response rate in patients with brain cancer. The company is concurrently advancing regulatory discussions with the FDA and reporting significant insider share purchases by its Chief Executive Officer.

Touch screen, finger, technology, concept. Stock photo illustrating NeOnc Technologies' other story.
NEONC TECHNOLOGIES HOLDINGS, INC. · Healthcare · Photo: geralt / Pixabay

Key highlights

  • Confirmed objective response rate increased to 12.5 percent from a previous 8.3 percent
  • Clinical study evaluated 24 patients using RANO 2.0 criteria for intranasal NEO100
  • FDA Type B End-of-Phase meeting scheduled for January 2027 to discuss Phase 3 trial design
  • CEO Amir Heshmatpour purchased 30,000 additional shares on the open market in November
  • Year-to-date insider buying by the CEO totals 371,000 shares valued at over $1.5 million

Clinical Trial Advancements

NeOnc Technologies reported updated interim results from its Phase 2a clinical study of intranasal NEO100, a drug candidate targeting malignant brain tumors. The latest analysis confirms an additional patient response, bringing the total to 3 out of 24 participants. This adjustment increases the objective response rate to 12.5 percent, up from the previously reported 8.3 percent. Responses were assessed using the Response Assessment in Neuro-Oncology 2.0 criteria. This update follows the initial topline results released in August 2026 and represents a continuing evaluation of the therapy's efficacy in high-need oncology segments.

Regulatory and Strategic Milestones

  • Type B End-of-Phase meeting with the FDA scheduled for early January 2027
  • Discussions to focus on potential accelerated approval pathways for NEO100
  • Planned presentation of Phase 3 confirmatory trial design to federal regulators
  • Advancement of oral candidate NEO212 toward Phase 2 clinical development
  • Maintenance of exclusive worldwide licensing for University of Southern California patents

Executive Conviction

“I’ve continued to buy NeOnc shares with my own funds because I believe in the work our team is doing for patients with brain cancer.”

Amir F. Heshmatpour, Executive Chairman, President and CEO, NeOnc Technologies

Financial and Market Position

NeOnc Technologies currently maintains a market capitalization of approximately 129.3 million dollars. The company's stock has demonstrated significant short-term momentum, recording a 64.7 percent increase over the past month. Insider activity has remained robust, with CEO Amir Heshmatpour acquiring 291,000 shares since the August trial data release. These open-market purchases were conducted using personal funds and did not involve the issuance of new equity. The company remains focused on its CNS cancer pipeline while operating with a technical RSI of 64.8, reflecting a period of increased investor attention.

Management commentary

“I’ve continued to buy NeOnc shares with my own funds because I believe in the work our team is doing for patients with brain cancer.”

Amir F. Heshmatpour, Executive Chairman, President and Chief Executive Officer
NEONC TECHNOLOGIES HOLDINGS, INC. · financial snapshot
Share price$4.48
Market cap$129M
Revenue (annual)$39,990
1-month price change+64.71%
SectorHealthcareBiotechnology

Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.

Source verified

SEC filing by NeOnc Technologies Holdings, Inc. announcing updated clinical trial data and insider share purchases.

Read the filing ↗

Track NEONC TECHNOLOGIES HOLDINGS, INC. live

Get the next NEONC TECHNOLOGIES HOLDINGS, INC. SEC filing seconds after it lands.

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.